Programmed Necrosis, Not Apoptosis, in the Heart
Abstract
It is well known that apoptosis is an actively mediated cell suicide process. In contrast, necrosis, a morphologically distinct form of cell death, has traditionally been regarded as passive and unregulated. Over the past decade, however, experiments in Caenorhabditis elegans and mammalian cells have revealed that a significant proportion of necrotic death is, in fact, actively mediated by the doomed cell. Although a comprehensive understanding of necrosis is still lacking, some key molecular events have come into focus. Cardiac myocyte apoptosis and necrosis are prominent features of the major cardiac syndromes. Accordingly, the recognition of necrosis as a regulated process mandates a reexamination of cell death in the heart. This review discusses pathways that mediate programmed necrosis, how they intersect with apoptotic pathways, roles of necrosis in heart disease, and new therapeutic opportunities that the regulated nature of necrosis presents.
As recently as 30 years ago, cell death was viewed as a passive and unregulated process. Irreversible cellular injury (from physical/chemical/biological insults) was thought to kill solely by overwhelming cellular homeostasis. In this model, the cell was merely the recipient of damage and not a participant in its own demise. Unexplained by this paradigm, however, were the highly reproducible deaths of specific cells during the development of multiple organisms. In fact, these developmental cell deaths (termed “programmed cell death”) had long been recognized but remained poorly understood. Studies in Caenorhabditis elegans showed that a relatively small network of genes (ced-9-|ced-4→ced-3) regulates the deletion of a specific 131 cells during development.1,2 These experiments provided the first evidence that any form of cell death was actively mediated.
Subsequent work demonstrated that these genes had been conserved for more than 600 million years of evolution to humans. The orthologs of ced-9, ced-4, and ced-3 are, respectively, the bcl-2 (B-cell lymphoma 2) family, apaf-1 (apoptotic protease activating factor-1), and the caspase family.3 Moreover, not only do these genes regulate developmental cell deaths in mammals, they also control the deaths of postnatal cells by a specific process termed apoptosis (discussed below). Taken together, these observations establish that cells often die through active mechanisms that have been highly conserved through evolution.
Research more than the past 2 decades has built on these observations to produce a relatively mature understanding of the pathways that mediate apoptosis. These include an intrinsic pathway, which is conserved back to C elegans, that uses mitochondria and endoplasmic reticulum; and an extrinsic pathway that involves cell surface death receptors. These pathways are critical in the regulation of apoptosis.3 Apoptosis is characterized by cell shrinkage and fragmentation into membrane enclosed apoptotic bodies that are phagocytosed. Plasma membrane integrity and organelle (eg, mitochondrial) morphology are maintained until late in the process, and inflammation is avoided. Based on morphology, however, it is clear that there are nonapoptotic forms of cell death including necrosis and possibly autophagic cell death.4 Although the existence of autophagic cell death has not been firmly established, necrosis has been recognized for more than a century. Necrosis is also evolutionarily ancient, dating back to C elegans5 or possibly earlier. The defining features of necrosis are defective plasma and organelle membranes, cell and organelle swelling, severe ATP depletion, and marked inflammation. Differential features of apoptosis and necrosis are summarized in Table 1.
Apoptosis | Necrosis | |
---|---|---|
Morphology | ||
Cell | Shrinkage | Swelling |
Mitochondria | Normal, although swelling possible late in the process | Marked swelling |
Chromatin condensation | Present, classically with margination | Usually not prominent |
Cell fragmentation | Membrane-enclosed apoptotic bodies | Cell rupture |
Membrane blebbing | Present | Not characteristic |
Membrane integrity | Intact in vivo; often lost at late time points (the latter especially in cell culture) | Defective at early stages |
Tissue inflammation | Classically absent, although exceptions | Severe |
Function | ||
Cellular ATP levels | Maintained | Markedly depleted |
Production of ATP | Usually maintained but may decrease | Markedly decreased |
Consumption of ATP | Decreased | Continues |
MPTP opening | May occur late, but not a defining feature | An early defining event in the mitochondrial necrosis pathway |
Loss of ΔΨm | May occur late, but not a defining feature | An early defining event in the mitochondrial necrosis pathway |
Apoptogen release | Present due to Bax/Bak-dependent OMM permeabilization | Not classic, but may be present because of OMM rupture following MPTP opening |
Caspase activation | Cascade of caspase activation critical for cell death | Not classically present but may occur with OMM rupture |
Activation of other proteases | May occur, eg, calpains | Calpains, cathepsins, and other lysosomal proteases sometimes activated and contribute to cell death |
Assays | ||
Morphology (light/electron microscopy) | Cell shrinkage and fragmentation, chromatin condensation with margination, plasma membrane blebbing | Cell swelling, organelle swelling, loss of plasma membrane integrity |
PI/trypan blue exclusion in nonpermeabilized cells (microscopy or flow cytometry) | PI/trypan blue excluded until late stages | PI/trypan blue not excluded even at early stages |
MPTP opening (eg, calcein release from matrix) | Not typical | An early event in necrosis |
Loss of ΔΨm (e.g. TMRE) | Sometimes present, but usually late | Occurs early |
Caspase activation (eg, Western blots, immunostaining, substrate assays) | Present | Not classically present but may occur with OMM rupture |
TUNEL | Present (reflects effector caspase activation) | Usually TUNEL negative but can occur if caspases are activated by OMM rupture |
Phosphatidylserine externalization (annexin V) | Annexin V–positive with intact plasma membrane integrity early in the process | Annexin V–positive, but usually with loss of plasma membrane integrity |
Extracellular markers (eg, release of HMGB1 [chromatin-associated protein], and cyclophilin A and LDH [cytoplasmic proteins]) | Absent, may occur late | Present |
Inhibitors | ||
Genetic | Bax/Bak knockout | CypD knockout (mitochondrial pathway) |
RIP3 knockout (death receptor pathway) | ||
Drugs | Caspase inhibitors | CsA (mitochondrial pathway) |
Nec-1 (death receptor pathway) |
Although their morphological definitions are distinct, apoptosis and necrosis are functionally connected at multiple levels. Hence, their differentiation may be difficult in some situations. Timing is an important factor, especially for cells in culture, where what begins as apoptosis can transition to necrotic morphology in the absence of corpse disposal mechanisms.
Based on its morphological and functional characteristics, it is not surprising that necrosis has been considered an “unregulated” or “accidental” form of cell death since Virchow described it. This view has been challenged over the past 10 years, however, by 3 independent lines of investigation. First, screens in C elegans have shown that necrosis is regulated by genes that encode plasma membrane and endoplasmic reticulum (ER) Ca2+ channels, calpains, and cathepsins, the unifying theme being elevated cellular Ca2+ concentrations.5–7 Second, biochemical studies of the apoptotic death receptor pathway revealed that this pathway is significantly more complex than initially thought.8 In addition to apoptosis, it can signal survival, necrosis, proliferation, and inflammation. This functional diversity reflects the participation of additional components in the pathway and more complex interactions among them. Third, deletion of ppif, encoding cyclophilin D, in the mouse proved the existence of a mitochondrial necrosis pathway.9–11 In apoptosis, the central mitochondrial event is permeabilization of the outer mitochondrial membrane (OMM). In contrast, the triggering mitochondrial event in necrosis is opening of an inner mitochondrial membrane (IMM) channel termed the mitochondrial permeability transition pore (MPTP). MPTP is regulated by cyclophilin D, which resides in the mitochondrial matrix.12
Taken together, this body of work strongly supports the concept of regulated or programmed necrosis. The existence of these necrosis pathways, however, does not imply that all necrosis is regulated. In contrast to apoptosis, which by definition is a controlled process, it is possible that some necrotic deaths are regulated, whereas others are not. For example, when a fly hits the windshield, does a regulated death program activate and, if so, does it have sufficient time to kill, or does the fly simply die from unregulated necrosis induced by massive trauma? The answer to this question is not known, nor is the proportion of necrotic deaths that are regulated versus unregulated. These considerations aside, a significant proportion of necrosis appears to be regulated and to play important roles in the pathogenesis of myocardial infarction,9,10 heart failure,13 stroke,11 neurodegenerative diseases,14,15 viral infection,16 muscular dystrophy,17 diabetes,18 and pancreatitis.19 More work is needed to understand the roles of necrosis in these diseases.
A large number of studies over the past 2 decades have examined the role of cardiac myocyte death in myocardial infarction and heart failure.20 The focus was on apoptosis because it was the only form of cell death that was thought to be regulated and, therefore, amenable to experimental manipulation. These studies concluded that apoptosis is an important component in the pathogenesis of myocardial infarction and heart failure. Necrosis, on the other hand, was largely ignored because it was believed to be unregulated. Although cardiac myocyte necrosis is thought to be the major pathological lesion in acute myocardial infarction, its significance in pathogenesis could not be formally evaluated until recently. Studies, in fact, show that regulated cardiac myocyte necrosis is an important component of myocardial infarction9,10 and perhaps heart failure.13
The recognition of necrosis as a regulated entity represents a paradigm shift in biology and medicine. From a fundamental perspective, this notion may provide new insights into how cells live and die while interacting with their environment. But, necrosis is also ubiquitous in disease. Thus, from a translational perspective, the concept of regulated necrosis may shed new light on disease pathogenesis and provide opportunities for therapeutics not thought possible in even the recent past. This review discusses the death receptor and mitochondrial necrosis pathways, how they connect with each other and with apoptosis pathways, and how necrosis may fit into the pathogenesis of the major cardiac syndromes.
Mechanisms of Necrosis: Death Receptor Pathway
Death Receptors
Recent data have shown that programmed necrosis can be stimulated by the same death ligands that activate apoptosis, such as tumor necrosis factor (TNF)α, Fas ligand (FasL), and TRAIL (TNF-related apoptosis-inducing ligand). Hence, the activation of death receptors can lead to different modes of cell death: apoptosis or programmed necrosis. Key issues include how death stimuli signal apoptosis and necrosis and how the downstream signaling pathways execute this decision. Programmed necrosis initiated by the ligation of TNF receptor (TNFR)1 has been most extensively characterized; thus, the discussion of death receptor–mediated necrosis focuses primarily on this pathway.
The TNFR superfamily consists of proteins with extracellular cysteine-rich domains that bind their respective ligands, and intracellular domains which initiate a signaling pathway that results in either cell survival or cell death. Two different TNFRs were cloned in 1990.21 One is TNFR1, which is expressed on most cell types, and the other is TNFR2, which is expressed predominantly on hematopoietic cells. TNFR1 contains a cytoplasmic death domain, whereas TNFR2 does not. The biological role of TNFR2 is not fully understood. TNFα administration can result in cell survival, apoptosis or programmed necrosis, depending on the cellular context.22 Thus, it is evident that an extensive network of molecular and biochemical events exist downstream of TNFR1 activation, and this dictates the execution of the appropriate biological response.
Receptor-Interacting Protein 1
Receptor interacting protein (RIP) kinases are serine/threonine kinases and constitute a family of seven members that are key regulators of cell survival and death.23 RIP1 was discovered 15 years ago as an interaction partner of Fas in a yeast two-hybrid screen.24 RIP1 consists of an N-terminal kinase domain, a RIP homotypic interaction motif (RHIM), and a C-terminal death domain (DD).25 The DD belongs to an evolutionarily conserved superfamily of death-fold motifs that also includes the caspase recruitment domain (CARD), the death effector domain (DED), and the pyrin domain (PYD). Death-fold motifs exhibit remarkably similar six antiparallel α-helical structures, despite dissimilar primary amino acid sequences. Primarily homotypic binding of death-fold motifs mediates protein-protein interactions. The DD of RIP1 was shown to be important for binding to the DD of death receptors including TNFR1 (Figure 1), Fas, and TRAILR1 and TRAILR2 (TNF-related apoptosis-inducing ligand receptors 1 and 2).24 The DD of RIP1 can also bind DD-containing adaptor proteins such as TNF-receptor-associated death domain (TRADD) and Fas associated via death domain (FADD).23,24 The serine/threonine kinase activity of RIP1 is necessary for programmed necrosis, but dispensable for both survival and apoptosis.26

Necrostatin (Nec)-1 is a potent small molecule inhibitor of programmed necrosis that functions by allosterically inhibiting the kinase activity of RIP1.27 Nec-1 blocks programmed necrosis without affecting RIP1-mediated survival, and therefore confirms the kinase-independent survival function of RIP1 and its kinase-dependent function in necrosis. Autophosphorylation on Ser161 within the activation loop of RIP1 is predicted to activate the kinase; yet, reconstituting RIP1-deficient cells with a phosphomimetic S161E RIP1 mutant cannot induce programmed necrosis by itself, suggesting that other factors are necessary.27 Nec-1 confers protection in experimental models of ischemic brain injury28 and myocardial infarction29 in vivo, underscoring the importance of the kinase activity of RIP1 for necrosis and its potential as a therapeutic target.
Receptor-Interacting Protein 3
RIP3, another member of the RIP serine/threonine kinase family, has recently been implicated as a crucial molecule in the induction of programmed necrosis. RIP3 has a unique C-terminus with a RHIM that facilitates its interaction with RIP1.30 Unlike RIP1, RIP3 does not have a DD.23 RIP1 and RIP3 share 33% similarity in amino acid sequence within their kinase domains; however, Nec-1 specifically inhibits the kinase activity of RIP1, but not RIP3.16,27
Recent work has shown that RIP3 is indispensable for TNFα-induced necrotic cell death.19 The expression of RIP3 correlates with the ability of cells to undergo necrosis induced by death receptors. Knockdown of RIP3 renders cells resistant to TNFα-induced necrosis. Conversely, reconstituting RIP3-deficient cells with wild type RIP3, but not a kinase-dead RIP3 mutant (K50A), enables cells to undergo necrosis in response to TNFα. Thus, the kinase activity of RIP3 is essential for death receptor–induced necrosis.16,19
RIP3 is phosphorylated on Ser199 during TNFα-induced necrosis. This phosphorylation event is critical for the subsequent cell death, and is most likely mediated by RIP3 autophosphorylation as it is ablated in RIP3 null cells reconstituted with a RIP3 kinase-defective mutant (D160N).25 However, RIP3 Ser199 phosphorylation during TNFα-induced necrosis is ablated by Nec-1, indicating that RIP1 kinase activity is also involved directly or indirectly in the phosphorylation of RIP3 Ser199.25
The homotypic interaction between RIP1 and RIP3 through the RHIM is also required for necrosis, and this interaction is detected only with necrosis-inducing stimuli.16,19 Nec-1 treatment inhibits both the interaction between RIP1 and RIP3 and RIP3 phosphorylation, suggesting that the kinase activity of RIP1 is required for the interaction of RIP1 and RIP3, and this interaction is required for the subsequent activation of RIP3.16,19
Distinct TNF Complexes
TNFα can induce several alternative outcomes: survival, apoptosis, or necrosis (Figure 1).21 Hence, the existence of distinct TNFα signaling complexes that lead to the activation of each of these alternative pathways has been investigated intensively.
On ligand binding, activated TNFR1 recruits multiple proteins, including TRADD, RIP1, cellular inhibitors of apoptosis 1 and 2 (cIAP1 and cIAP2), and TNFR-associated factors 2 and 5 (TRAF2 and TRAF5), to form complex I at the plasma membrane.8 cIAPs, which bind and inhibit active downstream caspases,31 also function as E3 ubiquitin ligases, catalyzing the formation of lysine 63 (K63) polyubiquitin chains onto Lys377 of RIP1.32,33 This K63-polyubiquitin chain promotes the recruitment of transforming growth factor-β-activated kinase 1 (TAK1)-binding proteins 2 and 3 (TAB2/3) and TAK1, which activate the IκB kinase (IKK) complex to trigger the activation of NF-κB that transcriptionally upregulates multiple survival genes.34 Therefore, RIP1 is thought to be necessary for NF-κB activation, although the kinase activity of RIP1 is dispensable. The necessity of RIP1, however, has recently been challenged.35
A second complex, known as complex II, is formed following endocytosis of complex I and subsequent dissociation from the receptor. TNFα-induced ubiquitination of RIP1 is dynamic and affects the transition from complex I to complex II. Several deubiquitinating enzymes, such as A2036 and cylindromatosis (CYLD),33 remove the K63-linked polyubiquitin chains from RIP1. This modification is a necessary step in the formation of complex II because knockdown of CYLD can protect cells against TNFα-induced apoptosis and necrosis, the 2 outcomes specified by complex II as is described below.37,38
FADD and procaspase-8 are recruited to complex II, leading to the initiation of apoptosis through forced proximity activation of procaspase-8.8,39 Active caspase-8 then proteolytically cleaves RIP1 and RIP3, thereby inactivating their kinase function and precluding the possibility of necrosis. In addition, caspase-8-induced cleavage of RIP1 produces a C-terminal fragment containing the DD, which further drives apoptosis by providing a platform for additional procaspase-8 activation.40
When caspase-8 is deleted or pharmacologically or genetically inhibited, complex II cannot initiate apoptosis, and thus TNFR1 ligation results in programmed necrosis in cell types competent to undergo necrosis.26,41 Critical events for necrosis take place in a necrosis-promoting signaling complex, termed the necrosome (Figure 2). In the necrosome, interdependent phosphorylation of RIP1 and RIP3 initiates necrosis as described above. The involvement of FADD or TRADD in programmed necrosis is less clear. FADD-deficient mouse embryonic fibroblasts (MEFs) are resistant to TNFα-induced programmed necrosis.40 On the other hand, the absence of FADD sensitizes Jurkat cells to TNFα-induced necrotic death.16,26 Moreover, RIP1 phosphorylation still occurs in TNFα-treated FADD-deficient Jurkat cells, which implies that RIP1 and RIP3 can be activated in the absence of FADD. In TRADD-deficient cells, both TNFα-induced apoptosis and necrosis are inhibited.42 This observation suggests that TRADD is essential in TNFα-induced cell death in certain experimental settings. However, in some cell types, knockdown of TRADD can stimulate the formation of complex II implying that the assembly and function of complex II does not rely on TRADD in these cell types.38 Although a basic understanding of complex II exists, many details await clarification.

Downstream Execution of TNFR-Induced Necrosis
Identifying the signaling events that occur downstream of the initiation of programmed necrosis is important in determining how necrosis is executed and for developing potential therapeutic reagents that can target specific events after the initial insult. We discuss several distinct molecular mechanisms that have been described to contribute to the execution of programmed necrosis (Figure 2).
Reactive Oxygen Species
RIP3 has been shown to be required for TNFα-induced reactive oxygen species (ROS) production during necrosis in several cell types, such as L929 murine fibrosarcoma cells, MEFs, and N-type NIH 3T3 cells.16,43 Moreover, RIP3 is found to interact with several metabolic enzymes, including glutamate ammonia ligase (GLUL), glutamate dehydrogenase 1 (GLUD1), and glycogen phosphorylase (PYGL).43 These enzymes are essential for the use of glutamate, glutamine, and glycogen, respectively, as energy substrates for ATP production in oxidative phosphorylation, a major source of ROS. The activation of these enzymes by RIP3 can elevate ROS production leading to TNFα-induced necrosis as a consequence of increased energy metabolism. Indeed, siRNA depletion of PYGL, GLUL, and GLUD1 reduced TNFα-induced ROS accumulation, correlating with a decrease in cell death.43
The production of ROS has been shown to be essential for TNFα-induced programmed necrosis in L929 cells and MEFs.44–46 Different sources of ROS generation have been reported to be critical including Nox1, an NADPH oxidase at the plasma membrane,47 and mitochondrial complex I.46 TNFα-stimulated ROS generation through Nox1 depends on RIP1,47 whereas TNFα stimulation of mitochondrial ROS requires the RIP1-RIP3 complex.16,43 The mechanism by which the RIP kinases affect mitochondrial complex I, however, remains unclear. Treatment with an antioxidant, such as butylated hydroxyanisole, reduces TNFα-induced ROS levels and necrosis in some cell types.45 However, not all cell lines are protected from programmed necrosis after antioxidant treatment,28 suggesting that TNFα-induced killing may be mediated by additional mechanisms.
Cellular Energetics, Poly(ADP-Ribose) Polymerase-1 Overactivation, and the Mitochondria
During apoptosis, ATP-consuming processes such as translation, proteasome function, and DNA repair, are minimized through caspase cleavage of specific proteins.48–50 On the other hand, ATP consumption persists during necrosis.51 Continued consumption of ATP during necrosis and impaired ATP production (discussed below) result in markedly decreased ATP levels. Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear protein that is activated during DNA repair and transcriptional regulation.52 Activated PARP-1 catalyzes the NAD+-dependent synthesis of poly(ADP-ribose) (PAR) onto target proteins resulting in depletion of cellular NAD+. The deficit of NAD+ decreases the rate of glycolysis because NAD+ is an essential cofactor for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Consequently, cells activate other pathways to produce NAD+, leading to excessive ATP consumption.53 This process has been shown to be involved in the necrotic death of L929 cells in response to TNFα, with PARP-1 overactivation perhaps resulting from ROS-mediated DNA damage.54 The same process may account for experimental ischemia/reperfusion injury in the brain, which is also accompanied by overactivation of PARP-1, and PARP-1 knockout reduces infarct size.55 Similarly, PARP-1 absence decreases myocardial infarction size following ischemia/reperfusion.56 Yet, necrosis induced by PARP-1 overactivation may not be solely attributable to the depletion of ATP. It has been demonstrated that overactivation of PARP-1 can increase mitochondrial complex I production of ROS.57 Ischemia/reperfusion-induced mitochondrial complex I defects are abrogated in PARP-1–deficient mice. Increased poly(ADP)-ribosylation of several mitochondrial proteins, including components of the electron transport chain, have been shown in rat liver mitochondria in response to H2O2 or NO, and may also further increase ROS production.58,59 In addition, RIP1 appears to mediate some instances of PARP-1–dependent necrosis. For example, MNNG (N-methyl-N′-nitro-N′-nitrosoguanidine), an alkylating agent, activates PARP-1 in MEFs resulting in cell death, which can be rescued by the absence of RIP1.60 In addition to the generation of mitochondrial ROS, PARP-1 overactivation can also induce necrosis through mitochondrial release of apoptosis inducing factor (AIF).61–64 The mechanism by which PARP-1 induces AIF release from the mitochondria is still controversial. The sequential activation of calpains and Bax was demonstrated to be crucial for the release of AIF.63 Other investigators, however, suggest that AIF release is induced by the PAR polymer.57 Following mitochondrial release, AIF translocates to the nucleus and, in conjunction with an endonuclease, carries out large-scale DNA cleavage. How AIF induces necrosis is not clear, however, but may involve further PARP-1 activation resulting from AIF-induced DNA damage.
RIP1-dependent signaling can also result in the inhibition of the adenine nucleotide translocase (ANT).65 ANT is an integral protein in the IMM that exchanges ATP synthesized in the matrix with cytosolic ADP.66 Therefore, a reduction of matrix ADP levels may occur through the inhibition of ANT by RIP1 activation. This, in turn, may lead to the reversal of the F1-Fo ATP synthase and hyperpolarization of the mitochondrial transmembrane potential (Δψm),67 which is observed during the early phases of programmed necrosis.68,69 RIP1-dependent inhibition of ANT requires the inclusion of the caspase inhibitor z-VADfmk with TNFα to induce necrosis. However, observations that z-VADfmk itself can interact with ANT raises questions about the general applicability of this mechanism. This will be resolved by testing other necrotic stimuli.
Proteases and Lysosomal Membrane Permeabilization
A proteolytic cascade occurs during apoptosis where the initiator caspases cleave and activate effector caspases. In contrast, a defined proteolytic cascade has not been discovered in the necrotic pathway. Nevertheless, proteases are involved in the execution of necrosis. Calpains are cytoplasmic noncaspase cysteine proteases that are ubiquitously and constitutively expressed in mammalian cells. Under normal conditions, calpastatin is the physiological inhibitor of calpains. However, when cytosolic Ca2+ levels increase, calpains are activated.70 Activated calpains can cleave the Na+/Ca2+ exchangers on the plasma membrane71 and mitochondria72 leading to Ca2+ overload in the cytosol and mitochondrial matrix respectively. The importance of calpain activation in necrotic cell death has been shown in neurons of C elegans,6 in dystrophin-deficient muscles of mice,73 and in high glucose-induced necrosis in LLC-PK1 cells.74 Moreover, in postischemic CA1 neurons of primates, activated calpains translocate to the lysosomal membrane75 cleaving a form of heat shock protein 70, a chaperone that controls lysosomal membrane integrity, and leading to lysosomal membrane permeabilization (LMP).76 Heat shock protein 70 overexpression has been shown to delay LMP and necrosis induced by TNFα or oxidative stress.77,78
The disruption of lysosomal membrane integrity allows for the release of proteases that contribute to necrosis.79 LMP can be induced by several factors including oxidative stress, lipids, and proteases,80 and can lead to cell death through several mechanisms. First, the rupture of lysosomes contributes to the acidification of the cell, which has been shown to be a requirement for necrosis in C elegans.81 Second, LMP is associated with the activation of phospholipase A2, which in turn increases the production of ROS.82 Third, LMP allows for a massive release of free iron, which through a Fenton-type reaction, produces reactive hydroxyl radicals.83 In fact, it has been observed in L929 cells that a sudden increase of free, cytosolic iron is important for TNFα-induced necrosis.84 Finally, LMP permits the release of proteases, such as cathepsins, into the cytosol allowing for cleavage of various proteins. Ischemic injury in neurons results in the release of cathepsins from lysosomes, and cathepsin inhibitors significantly attenuate neuronal necrosis.85 These data suggest an important role for cathepsins in the execution of necrotic cell death.
Phospholipases, Lipoxygenases, and Sphingomyelinases
A key feature of necrosis is the disruption of organelles and plasma membranes. Lipid peroxidation appears to be a mechanism of membrane disruption in necrosis that can be mediated by lipoxygenase.86,87 TNFα has been shown in L929 cells to activate phospholipase A2, a family of esterases that produces arachidonic acid from phospholipids.88,89 Arachidonic acid is acted on by lipoxygenase, thereby generating ROS and contributing to lipid peroxidation and the disruption of membranes.87
Ceramide is a second messenger that elicits pleiotropic effects during necrosis, including activation of nitric oxide synthase, lipid peroxidation, mitochondrial ROS production,90 and calpains.91 Ceramide can be generated by sphingomyelinase-catalyzed hydrolysis of sphingomyelin, a membrane sphingophospholipid. There are several isoforms of sphingomyelinase that are distinguishable by their subcellular localizations and pH optima. A neutral sphingomyelinase is found at the plasma membrane and an acid sphingomyelinase is localized in the endosomal-lysosomal compartment. A significant increase in ceramide levels has been observed during TNFα-induced necrosis in many cell types, including L929 cells, NIH3T3 fibroblasts, and human Jurkat T cells, and the accumulation of ceramide seems to be more pronounced when caspases are inhibited.92–94 Cells deficient in acid sphingomyelinase or treated with acid sphingomyelinase inhibitors are more resistant to TNFα/z-VADfmk-induced necrosis,94 as are cells overexpressing acid ceramidase, which degrades ceramide.93 Interestingly, depletion of RIP1 confers protection against ceramide accumulation and necrotic cell death induced by TNFα/z-VADfmk in many cell types,94 suggesting that RIP1 is essential for the induction of ceramide production in TNFα-mediated necrosis.
Mechanisms of Necrosis: Mitochondrial Pathway
Key Mitochondrial Events in Necrosis and Apoptosis
In addition to their role in coupling substrate catabolism with ATP production, mitochondria are intimately involved in regulated forms of cell death. The major mitochondrial event in apoptosis is permeabilization of the OMM. In contrast, the defining mitochondrial event in necrosis is the opening of a channel in the IMM, called the mitochondrial permeability transition pore (MPTP) (Figure 3). Although the biochemical events that mediate OMM permeabilization during apoptosis are poorly understood,95 it is clear that the process is triggered by Bax and Bak, proapoptotic multidomain Bcl-2 proteins. OMM permeabilization allows for the release of mitochondrial apoptogens, such as cytochrome c, into the cytoplasm. These apoptogens promote caspase activation and cell death via the mitochondrial apoptosis pathway. On the other hand, the distinct IMM events that mediate the mitochondrial necrosis pathway is discussed in this section.

Effects of MPTP Opening on Mitochondrial Structure and Function
Although the unpermeabilized OMM does not allow for the passage of apoptogens, such as cytochrome c, it is permeable to ions and small molecules.96 Hence, the cytoplasm is isoelectric with respect to the mitochondrial intermembrane space. In contrast, the IMM in a healthy mitochondrion is impermeable to small molecules and even protons, resulting in an electric and chemical gradient between the intermembrane space and matrix. In particular, the passage of electrons during respiration generates a proton gradient rendering the matrix negative, and this electric potential difference (termed Δψm) drives the conversion of ADP to ATP. Maintenance of IMM integrity is critical. Conversely, opening of MPTP causes an acute derangement in mitochondrial structure and function that leads to necrotic cell death.
The immediate consequences of MPTP opening include: (1) collapse of Δψm, leading to cessation of respiration-driven ATP synthesis and reversal of the FoF1-ATP synthase; (2) redistribution of solutes and ions across the IMM; and (3) entry of large amounts of water into the solute-rich matrix to normalize the osmotic gradient. This entry of water results in matrix swelling and expansion of the redundant IMM. Because the OMM lacks the redundancy of the IMM, IMM expansion can lead to OMM rupture and the release of apoptogens, including cytochrome c, into the cytosol. In contrast, the release of apoptogens during apoptosis involves Bax/Bak-dependent OMM permeabilization (not rupture) and usually occurs before loss of Δψm. Nevertheless, release of apoptogens attributable to OMM rupture following MPTP opening can trigger apoptosome assembly and caspase activation.9 Although severe ATP depletion and loss of plasma membrane integrity are primarily responsible for cell death in necrosis, it is possible that activation of downstream apoptotic signaling also contributes.
The major regulator of MPTP opening is matrix Ca2+.97 Multiple additional factors strongly influence pore opening, however, and are thought to work through modulating sensitivity to Ca2+.98 Thus, oxidative stress, increased phosphate, and adenine nucleotide (ATP and ADP) depletion augment Ca2+ sensitivity to pore opening, whereas acidosis does the opposite.99
Ca2+ overload during ischemia is promoted by anaerobic metabolism, lactate production, and intracellular acidosis. H+ is pumped out of the cell by the Na+/H+ exchanger, which in combination with malfunctioning Na+/K+ ATPase (attributable to ATP depletion) results in increased intracellular Na+. Na+ is subsequently exchanged for Ca2+ by reverse operation of the sarcolemmal Na+/Ca2+ exchanger, resulting in intracellular Ca2+ overload. Additional elevations in intracellular Ca2+ result from Ca2+-induced Ca2+ release from the endoplasmic reticulum/sarcoplasmic reticulum (ER/sarcoplasmic reticulum). Moreover, ischemia results in ATP depletion and ROS generation, the latter further exacerbated during reperfusion. Finally, the ischemia-induced acidosis is normalized by reperfusion. All of these events favor MPTP opening.100 Some of the mechanisms by which these parameters operate are considered below.
Components of MPTP: Past and Present
The conceptual basis of MPTP had its origins in experiments performed a half-century ago, in which Ca2+ was noted to trigger marked mitochondrial swelling.101,102 Although various models were considered to explain this observation, the data were most consistent with a nonspecific, high-conductance channel in the IMM. Subsequent experiments demonstrated that this channel could accommodate the passage of molecules <1500 Da.103 Despite considerable effort, the components of MPTP are still not known with certainty. A number of proteins have been hypothesized to comprise and/or regulate this pore including ANT, phosphate carrier (PiC), voltage-dependent anion channel (VDAC), peripheral benzodiazepine receptor, and cyclophilin D. A combination of biochemical and gene knockout studies, however, has ruled out an essential role for many of these proteins as components of the channel, although suggesting a regulatory role for some.
Adenine Nucleotide Translocase
As noted previously, ANT, the most abundant protein in the IMM, functions as an ADP/ATP exchanger. The involvement of ANT in MPTP is supported by correlations between ANT conformation and MPTP opening.104 The ANT ligand carboxyatractyloside stabilizes the cytosolic (“c”) conformational state and stimulates MPTP opening. Conversely, the ANT ligand bongkrekic acid stabilizes the matrix (“m”) conformational state, and inhibits MPTP opening. Ca2+, the major trigger for MPTP opening, stimulates the c conformation of ANT. Although ANT lacks traditional Ca2+ binding motifs, it is possible, but unproven, that Ca2+ binds ANT through carboxyl groups on aspartic acid and glutamic acid residues facing the matrix.105 In addition, the binding of adenine nucleotides to ANT decreases the sensitivity of Ca2+-induced MPTP opening. Oxidative stress, which potentiates Ca2+-induced MPTP opening,104 also stimulates disulfide bond formation between matrix-facing cysteine160 and cysteine257 in rat ANT1,106 interfering with the binding of adenine nucleotides to ANT. Although the above data are correlative, they link certain conformational or post-translational states of ANT with MPTP opening, suggesting that ANT is part of MPTP. In contrast, genetic experiments raise significant questions about the necessity of ANT for MPTP function. Initially, there were believed to be 2 mouse ANT genes, ANT1 and ANT2. Mitochondria derived from mice lacking ANT1 and ANT2 still demonstrate MPTP opening in response to Ca2+, suggesting that ANT is not an essential component of MPTP.107 However, the more recent discovery of a third mouse ANT gene, ANT4,108 raises questions concerning redundancy. Whether or not ANT is essential for MPTP opening, it modulates this channel as mitochondria from the ANT1-ANT2 double knockout exhibit reduced Ca2+ sensitivity of MPTP opening.107 In conclusion, ANT is not believed to be a critical component of MPTP, but probably plays a regulatory role.
Voltage-Dependent Anion Channel
VDAC, the most abundant protein in the OMM, functions as a low specificity pore allowing the passage of molecules <5kDa. VDAC was noted to copurify with ANT,109 suggesting that these proteins may interact at contact sites between the OMM and IMM. However, deletion of all 3 mouse VDAC genes (VDAC1, VDAC2, VDAC3) does not affect Ca2+- and oxidative stress–induced MPTP opening, indicating that VDAC is dispensable for MPTP function.110,111
Cyclophilin D
Cyclophilin D, encoded by the nuclear gene ppif, is a peptidylprolyl cis-trans isomerase that resides in the mitochondrial matrix.112,113 Its normal physiological functions are not known with certainty, but some data support a role in Ca2+ efflux.114 Cyclophilin D interacts with ANT and the phosphate carrier (see below).115 The drug cyclosporin A binds to cyclophilin D and inhibits Ca2+-induced MPTP opening.116 Deletion of ppif renders mitochondria highly resistant to Ca2+-induced MPTP opening,9,10 although this will still occur at high Ca2+ concentrations. Conversely, cyclophilin D overexpression induces MPTP opening in the absence of an inciting death stimulus.9 Thus, cyclophilin D plays an important role in promoting MPTP opening. The prolyl isomerase activity of cyclophilin D is important in this function because reconstitution of ppif null cells with wild type, but not isomerase-deficient, cyclophilin D restores MPTP opening.9 Absence of cyclophilin D does not affect classic mitochondrial apoptotic responses such as cytochrome c release in response to Bax, nor does it protect cells against traditional apoptotic stimuli such as staurosporine. In contrast, the absence of cyclophilin D protects cells in culture and in vivo against necrotic stimuli, whereas overexpression of cyclophilin D does the opposite.9 These results indicate that cyclophilin D is a key regulator of MPTP and necrotic, but not apoptotic, cell death. The fact that MPTP opening can still proceed in the absence of cyclophilin D argues strongly against an essential structural role in the pore.
Phosphate Carrier
PiC is an IMM protein that transports inorganic phosphate (Pi). The ability of the Pi to promote MPTP opening is well known,1,101 More recently, it has been shown that, surprisingly, Pi is also important for desensitization of Ca2+-induced MPTP opening by cyclosporin A or deficiency of cyclophilin D.117 In fact, PiC binds cyclophilin D in a cyclosporin A-inhibitable manner. In addition, ANT and cyclophilin D interact.115 ANT also binds PiC in a cyclosporine A-independent manner. Thus, it is possible that ANT, PiC, and cyclophilin D form a complex. As previously discussed, ANT and cyclophilin D are not essential for MPTP but play important regulatory roles. The necessity of PiC has yet to be tested in knockout studies. Therefore, one model is that PiC or another yet to be determined protein is an essential MPTP constituent. In this model, the prolyl isomerase activity of cyclophilin D would conformationally regulate PiC, ANT, or both. The mechanism by which Ca2+ would activate the pore is unknown. Drugs that inhibit cyclophilin D might work through disrupting its interaction with the complex (cyclosporin A) or inhibiting its isomerase activity (sanglifehrin A).118
Summary of MPTP Function and Regulation
There are multiple open questions. Most important, the essential components of the MPTP have not been delineated unambiguously. Genetic studies exclude VDAC and probably ANT as essential components, although ANT may play a regulatory role. Pore opening is not absolutely dependent on cyclophilin D, suggesting that cyclophilin D is not an essential component. However, cyclophilin D is clearly a key regulator. The characteristics of PiC suggest that it may be a core component, but genetic loss of function studies will be needed to test this. Thus, the possibility remains that an essential protein is yet to be identified. Ca2+ is an important trigger for MPTP opening, but it is not clear if its critical targets are PiC, ANT, cardiolipin, or another moiety.
Explaining the Necrosis Phenotype
The major manifestations of necrosis are severely decreased cellular ATP levels, defects in membrane integrity, and inflammation.
ATP Depletion
As we have already discussed the bioenergetics of necrosis, the key findings are summarized here. Severe decreases in ATP synthesis can result from RIP1-dependent ANT inhibition65 as well as MPTP opening and its consequences.119 Moreover, whatever ATP remains in necrotic cells is squandered by the continued operation of expensive cellular processes such as DNA repair, translation, and others, processes that are halted during apoptosis by caspase cleavage of key proteins.48–50 Thus, cellular ATP depletion during necrosis involves both mitochondrial and peripheral components.
Membrane Dysfunction
Necrosis also involves defects in the integrity of plasma membranes (resulting in loss of cellular homeostasis and cell swelling), ER membranes (resulting in increased intracellular Ca2+), and lysosomal membranes (resulting in the release of proteases such as cathepsins). This aspect of the necrotic phenotype is very important but not well understood. Aspects of the molecular mechanism have been reviewed above. In addition to these factors of general interest, mechanical stress can contribute to plasma membrane leakiness in striated muscle cells. The sarcolemma of actively contracting cells is susceptible to damage. For example, transient leakiness of the cardiac sarcolemma can be induced by exercise and β-adrenergic stimulation in rats.120 Membrane stress attributable to ischemic contractures during infarction may contribute to plasma membrane defects.
Moreover, skeletal and cardiac myocytes in patients experiencing a variety of muscular dystrophy syndromes exhibit increased sarcolemmal fragility.121 Plasma membrane damage in these situations is counteracted by ongoing repair mechanisms involving dysferlin122,123 and mitsugumin 53.124–127 Sarcolemmal abnormalities in animal models of muscular dystrophy appear to activate necrosis signaling as evidenced by increased cellular Ca2+128 and swollen mitochondria.17 Although deletion of ppif does not correct the genetically determined plasma membrane dysfunction, it improves mitochondrial abnormalities and ameliorates muscle degeneration.17 These studies underscore that mechanical stress in muscle cells may be an important factor in plasma membrane dysfunction leading to necrosis.
The muscular dystrophy work also unmasks a bidirectional relationship between necrosis signaling and plasma membrane defects. Traditionally, we think of necrosis pathways as inducing plasma membrane dysfunction. However, the baseline plasma membrane dysfunction in muscular dystrophy appears to activate necrosis pathways, which play an important role in pathogenesis. Thus, it would appear that activation can proceed bidirectionally. This model predicts that key membrane-associated proteins as well as components of the endogenous membrane repair systems might be targets of proteases activated during necrosis in heart failure unrelated to the various dystrophic syndromes. In fact, dystrophin cleavage has been observed in patients with idiopathic heart failure.129
Inflammation
As described previously, apoptosis has traditionally been considered a death process that avoids inflammation, whereas necrosis is highly inflammatory. Although this dichotomy is accurate as a first approximation, recent observations suggest increased complexity regarding the occurrence of inflammation in apoptosis and necrosis. As the details of the postdeath clean-up operation, including recruitment of inflammatory cells and phagocytosis, are beyond the scope of this review, we summarize several key points. The reader is referred to an excellent recent essay for an in-depth consideration of this area.130
The essential principle is that a combination of factors determines whether dying cells undergo silent (no inflammation) removal versus noisy (marked inflammation) removal. These include the active release of soluble “find me” signals to attract phagocytes. For example, “find me” signals in apoptosis include lysophosphatidylcholine and sphingosine-1-phosphate, which attract macrophages while altering their release of cytokines to avoid inflammation.131 “Eat me” signals to induce phagocytosis include phosphatidylserine132 displayed at the surface of apoptotic cells. “Eat me” signals bind to specific serum proteins and interact with receptors on phagocytes triggering engulfment. Silent removal may also be the fate of cells undergoing necrosis that have not yet lost plasma membrane integrity when these cells exhibit phosphatidylserine at the cell surface133 thereby facilitating phagocytosis.134 In contrast, necrotic cells that have undergone plasma membrane permeabilization release a variety of proteins and nucleic acids factors that are not only markers of membrane dysfunction, but also mediate the inflammatory response. For example, the release of the histone-associated protein HMGB1 (high-mobility group protein B1) stimulates inflammation through multiple mechanisms involving Toll-like receptors and Receptor for Advanced Glycation End-products.
Connections Between Cell Death Pathways
Peripheral Signaling Pathways That Can Regulate Apoptosis and Necrosis
Multiple signaling pathways affect both apoptosis and necrosis and often exert concordant effects.
Akt and Pim-1
The serine/threonine kinase Akt inhibits apoptosis through its phosphorylation of specific targets, which alters the function and/or subcellular localizations of these proteins (eg, FoxO [forkhead box O], Bad [Bcl-2 associated agonist of cell death], Bax, glycogen synthase kinase [GSK3]β).135 Akt can also translocate to the mitochondrial matrix and inhibit MPTP opening, but its targets in this situation are unknown.136 Similarly, Pim-1, itself a serine/threonine kinase and downstream effector of Akt, antagonizes apoptosis through substrates that are distinct from, and overlap with, those of Akt.137 Pim-1 also translocates to the mitochondria following ischemia/reperfusion and inhibits MPTP opening through an unknown mechanism.
Protein Kinase C-ε
Protein Kinase (PK)C-ε inhibits MPTP opening, an effect requiring its kinase activity.138 In this case, there are some hints as to mechanism: PKC- ε interacts with ANT1, VDAC1, and hexokinase II, and recombinant PKC- ε can phosphorylate VDAC1. Under hypoxic conditions, PKC- ε can also associate with and phosphorylate cytochrome oxidase (mitochondrial complex IV).139 The mechanistic relationships between these phosphorylation events and MPTP opening, however, are unclear.
Glycogen Synthase Kinase 3β
GSK3β promotes apoptosis (eg, by phosphorylating Bax and facilitating its mitochondrial translocation).140 GSK3β is also an important point of convergence for multiple signals that regulate MPTP opening in cardiac myocytes.141 Specifically, GSK3β inactivation by phosphorylation (pharmacological agents) or knockdown with RNAi decreases the sensitivity of MPTP opening. Although the underlying molecular mechanism has not yet been delineated in cardiac myocytes, an association has been identified in cancer cells.142 GSK3β interacts with cyclophilin D, which becomes phosphorylated, but it is not known whether phosphorylation of cyclophilin D is responsible for the increased sensitivity of MPTP opening.
Connections Between Death Receptor and Mitochondrial Necrosis Pathways
The death receptor and mitochondrial necrosis pathways are functionally interconnected. Necrosis induced by the TNF death receptor pathway (TNFα/SMAC-mimetics/z-VADfmk) is substantially rescued in MEFs lacking cyclophilin D.19 RIP1 is necessary for MNNG-induced loss of Δψm, suggesting a connection between RIP1 and MPTP opening.60 Administration of nec-127 reduces infarct size in wild type mice subjected to ischemia/reperfusion injury, but does not reduce infarct size further in mice already cardioprotected because of the absence of cyclophilin D.143 These observations suggest that RIP1 and cyclophilin D reside in the same genetic pathway, although the molecular connections await elucidation.
The death receptor and mitochondrial necrosis pathways are connected through several potential mechanisms. One possible connection is ROS. As previously described, RIP3 binds and activates catabolic enzymes that generate ROS, and ROS increases the sensitivity of MPTP opening.43 A second connection may be provided by other substrates of RIP3 which have yet to be identified. Some may be components of the mitochondrial death machinery or regulate these components indirectly. A third possibility is RIP1, which can translocate to the mitochondria in response to TNFα.65 Although possible effects of RIP1 on ANT have been discussed previously, its localization at the mitochondria may provide an opportunity for additional regulation.
Connections Between Apoptosis and Necrosis: Death Receptor Pathway
The death receptor apoptosis and necrosis pathways are intimately connected through multiple shared constituents (ligands, receptors etc;Figure 1). They differ with respect to some of the complexes that are formed (eg, necrosome;Figure 2). The decision to die through either death program is driven, in part, by K63-deubiquitination of RIP1 and the transition from complex I to complex II. The choice to undergo apoptosis rather than necrosis, however, is determined by whether caspases are activated, and RIP1 is cleaved. Thus, in the death receptor pathway, necrosis is a default outcome when apoptosis is inhibited.
The death receptor apoptosis and necrosis pathways are also linked by Bmf (Bcl-2-modifying factor), a BH3-only member of the Bcl-2 family.144 In healthy cells, this protein is sequestered on the myosin V-actin motor complex, but is released to translocate to mitochondria and induce apoptosis in response to stimuli such as anoikis. Bmf appeared in an siRNA screen for mediators of death receptor–induced necrosis and was confirmed to be necessary for this form of cell death, although the mechanism is not known.37
Connections Between Apoptosis and Necrosis: Mitochondrial Pathway
In contrast to the death receptor pathway, it appears that either apoptosis or necrosis can be a primary outcome in the mitochondrial pathway. Therefore, a mechanism may exist to coordinate these processes in this pathway, but its molecular nature is not understood.
Connections Between Outer and Inner Mitochondrial Membranes
As apoptotic OMM and necrotic IMM events are separated by only microns, one would expect cross-talk between these processes. We discuss examples of signaling between Bcl-2 proteins on the OMM and ANT on the IMM; how necrotic mitochondrial events can activate downstream apoptosis signaling; and how caspase cleavage during apoptosis could produce a necrotic phenotype.
During apoptosis induced by growth factor withdrawal or etoposide, ADP/ATP exchange by ANT decreases. Antiapoptotic Bcl-2 and Bcl-xL interact with ANT and stimulate ADP/ATP exchange. These findings were interpreted a decade ago to indicate a relationship between energetics and cellular viability.145 An additional possibility is that this mechanism provides a way for antiapoptotic Bcl-2 proteins to prevent initiating events that could induce necrosis (eg, ANT inhibition, see above). Further insights may result from using mutants that separate effects of Bcl-2 or Bcl-xL on ANT from their effects on OMM integrity.
As discussed, MPTP opening can result in sufficient mitochondrial swelling to rupture the OMM allowing the release of apoptogens.9 In the cytoplasm, cytochrome c triggers apoptosome assembly and activation of procaspases-9 and -3. Thus, the mitochondrial events of necrosis can activate downstream apoptosis signaling. Although caspase activation may contribute to cell death, its importance is not clear in the context of the other cellular consequences of necrosis.
NADH dehydrogenase (ubiquinone) Fe-S protein 1 (NDUFS1 or p75), a component of mitochondrial complex I, is a caspase-3 substrate that gets cleaved during staurosporine-induced apoptosis. NDUFS1 faces the mitochondrial intermembrane space, and caspase-3 presumably gains access during apoptosis through the already permeabilized OMM. Cleavage of NDUFS1 disrupts electron transport leading to ROS production, loss of Δψm, mitochondrial swelling (consistent with MPTP opening), decreased ATP levels, and defective plasma membrane function, all features of necrosis. Expression of a noncleavable mutant of NDUFS1 (on the wild type background) maintains Δψm, ATP levels, and mitochondrial morphology, limits ROS production, and delays plasma membrane leakiness.146 The fact that these effects occur early in this model support their relevance to cell killing. However, the overall importance of these events to the mechanisms by which apoptosis brings about cell death is not clear.
Proteins That Activate Both Apoptotic and Necrotic Signaling
Bak resides constitutively in the ER membrane and OMM, and Bax trafficks to these locations in response to some death stimuli.95 In addition to their role in promoting OMM permeabilization and apoptogen release, Bax and Bak also exert effects on ER Ca2+ handling and cell death. Thus far, the details of this process have been studied only in MEFs.147,148 An important mechanism for ER-mediated cell killing is the transfer of a bolus of Ca2+ from ER to mitochondria, either through the cytoplasm or via direct connections between the 2 organelles. The delivery of Ca2+ to the mitochondria may trigger necrosis through MPTP opening and possibly apoptosis through unknown mechanisms. Antiapoptotic Bcl-2 inhibits ER-mediated cell death by interacting with the type 1 inositol-1,4,5-triphosphate receptor (IP3R-1) to induce a Ca2+ leak.149 The resulting decrease in baseline ER luminal Ca2+ concentration limits the magnitude of the Ca2+ bolus elicited by death stimuli relevant to this pathway (eg, oxidative stress, lipids), and cell death is blunted. In contrast, in the presence of proapoptotic Bax, Bcl-2 dissociates from IP3R-1 abrogating the Ca2+ leak. The baseline ER luminal Ca2+ concentration increases as does the bolus of released Ca2+ and amount of cell death elicited by a death stimulus.
Standard BH3-only proteins induce apoptosis, and this requires the BH3 domain, which mediates interactions with Bax or Bak. In contrast, BH3-only-“like” proteins possess an atypical BH3 domain,12 which is not required for killing.150 Cell death induced by BH3-only-like proteins can exhibit features of apoptosis or necrosis. Nix/BNip3L, a BH3-only-like protein, is induced in cardiac myocytes by hypertrophic stimuli.151 Nix/BNip3L overexpression elicits heart failure primarily resulting from cell death,151 whereas cardiac-specific deletion of Nix ameliorates cardiomyopathy induced by hemodynamic overload.152,153 Nix/BNip3L is normally found at the OMM and ER membrane.154 Targeting Nix/BNip3L to mitochondria versus ER shows that it is capable of inducing more than one type of cell death (Figure 4).155 Mitochondrially-targeted Nix/BNip3L causes Bax/Bak-dependent OMM permeabilization, apoptogen release, caspase activation, and apoptosis. In contrast, ER-targeted Nix/BNip3L triggers MPTP opening, swollen mitochondria, and cytochrome c release independent of Bax/Bak and presumably attributable to OMM rupture. Ca2+ was not examined in this study. But, an earlier report showed that Nix/BNip3L null cells have reduced levels of ER Ca2+ and cell death, and Ca2+ repletion partially restores killing.154 Thus, apoptotic or necrotic cell death is induced depending on whether Nix/BNip3L is mitochondrially or ER-localized.

The ability of Nix/BNip3L to induce a mixed death phenotype in a population of cells is interesting and raises some mechanistic questions. Standard BH3-only proteins (eg, BimEL, PUMA) targeted to the ER require Bax or Bak specifically at the ER to kill.156 Thus, it is curious that ER-targeted Nix/BNip3L can induce cell death in the absence of Bax and Bak. In contrast, mitochondrially-targeted Nix/BNip3L still requires Bax or Bak to affect cytochrome c release. The reasons for this difference are not clear, but may be related to fundamental differences between BH3-only and BH3-only-like proteins. These studies highlight that various proapoptotic Bcl-2 proteins can activate central events in apoptosis signaling at the mitochondria as well as critical ER to mitochondrial signaling that induces necrosis. The mechanisms that coordinate these seemingly disparate instructions are not understood. Do signals suppress one death process to allow the other to proceed? Or do both processes proceed with the effects of one dominant over the other? Additional work will be needed to sort this out.
Necrosis in Heart Disease
Numerous studies have demonstrated that cell death is an important component in the pathogenesis of myocardial infarction and heart failure.20 Although a variety of cell types may be involved, this discussion focuses on cardiac myocytes. The magnitude and kinetics of cell death during myocardial infarction and heart failure differ greatly. Myocardial infarction is characterized by a large burst of cardiac myocyte death that takes place in the 24 hours following the onset of ischemia.157 In contrast, failing hearts exhibit ongoing cardiac myocyte death over months to years at levels that are low but still 100-fold higher than those seen in nonfailing hearts.158 The recognition that not only apoptosis, but also necrosis, may be actively mediated has renewed interest in the role of regulated cell death in heart disease. Specifically, which cell death processes operate during myocardial infarction and heart failure and, based on this, which antideath strategies may be therapeutically useful (Table 2).
Disease | Disease Model and Methods | Results | References |
---|---|---|---|
Myocardial infarction | Isolated perfused rat hearts | MPTP closed during ischemia; open during reperfusion | 100 |
30 min I/15 min R | |||
Isolated mitochondria incubated with 2-deoxy-[3H]glucose, which enters mitochondrial matrix when MPTP open | |||
Isolated perfused rat hearts | LVDP improved by CsA | 169 | |
30 min I/15 min R±CsA | |||
Isolated perfused rat heart | Infarct size decreased by CsA and sanglifehrin A | 170,171 | |
30 min I/4 h R CsA initiated at reperfusion | |||
35 min I/120 min R sanglifehrin A initiated at reperfusion | |||
Isolated perfused rat heart | Decreased LDH release and improved function by sanglifehrin A | 118 | |
30-min global I sanglifehrin A initiated at reperfusion | |||
Mice in vivo 60 min I/24 h R wild type vs ppif−/−±CsA | ppif−/− 40% reduction in infarct size, similar to protection with CsA in wt | 9 | |
Mice in vivo 30 min I/2 h R wild type vs ppif−/− | ≈80%reduction in infarct size in ppif−/− | 10 | |
Mice in vivo | Infarct size reduced by nec-1 in wild type | 143 | |
30 min I/2 h R | |||
Wild type vs ppif−/− with or without Nec-1 | Nec-1 did not further decrease infarct size in ppif−/− | ||
Mice in vivo | Infarct size greater in the TNFR1/TNFR2-deficient mice compared to wild type | 163 | |
24-h permanent occlusion | |||
Wild type vs TNFR1/R2 knockout | |||
Humans | CK release and infarct size- reduced in CsA-treated patients | 172 | |
Patients with STEMI | |||
Saline vs CsA immediately before PCI | |||
Infarct size evaluation by MRI | |||
Heart failure | Mice in vivo | CypD deletion rescued myocardial necrosis and heart failure | 13 |
Transgenic overexpression of L-type Ca2+-β2a subunit | Bcl overexpression did not rescue | ||
Mice in vivo | Increase susceptibility to heart failure induced in ppif−/− | 114 | |
TAC and swimming protocol | |||
Wild type vs ppif−/− |
Some, but not all, studies are discussed in text. CK, creatine kinase; I/R, ischemia/reperfusion; ppif, peptidylprolyl isomerase f; LAD, left anterior descending artery; LDH, lactate dehydrogenase; LVDP, left ventricular developed pressure; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TAC, transaortic constriction.
Recognizing Cell Death Programs In Vivo
Apoptosis and necrosis can be identified in cell culture systems using established morphological and biochemical markers (Table 1). For apoptosis, these include chromatin condensation, cell shrinkage and fragmentation, cytochrome c release, caspase activation, cleavage of caspase substrates, cell surface exposure of phosphatidylserine (Annexin V binding), and DNA cleavage (eg, TUNEL). Necrosis indicators include cell and organelle swelling, MPTP opening, loss of Δψm, decreased cellular ATP levels, loss of membrane integrity, and release of endogenous proteins such as creatinine kinase, lactate dehydrogenase, troponin, HMGB1, and cyclophilin A.159 Even in cultured cells, however, the separation between apoptosis and necrosis is not as clean as might be expected. For example, cytochrome c release can result from both apoptotic OMM permeabilization and necrotic OMM rupture, such that the resulting caspase activation, cleavage of caspase substrates, and TUNEL may not be specific for either form of cell death. Conversely, loss of Δψm, a primary feature of necrosis, can occur late in apoptosis. Timing can also be an important factor. When the disposal of corpses is slow (or nonexistent as in cell culture), cells in late phases of apoptosis can lose membrane integrity and transition toward a necrotic phenotype. For this reason, it is important to analyze cell death early in the process and, optimally, at more than a single time point.
In addition to these generic ambiguities, the in vivo setting presents additional challenges in differentiating between apoptosis and necrosis. First, the sensitivities and optimal time windows of markers vary, confounding direct comparison of apoptosis versus necrosis. Second and most important, there is currently a paucity of necrosis markers for in vivo studies. Although general markers (eg, the release of “cardiac enzymes” into the circulation and histological evidence of myocardial inflammation) exist, other more specific indicators (eg, release of HMGB1) have been problematic in the in vivo setting. There has been some success, however, in documenting myocardial necrosis by the in vivo administration of antimyosin antibodies or Evans blue (becomes bound to albumin in vivo) to assess plasma membrane integrity. Because of these issues, electron microscopy is sometimes used. This allows apoptosis and necrosis to be assessed using a single technique, although sensitivities of detection of apoptotic and necrotic cells differ.
Myocardial Infarction
Only limited information exists concerning the frequencies of cardiac myocyte necrosis and apoptosis in myocardial infarction. Necrosis has traditionally been considered the means by which cardiac myocytes die during myocardial infarction. These observations predate the recognition of apoptosis as an entity and necrosis as a regulated process. The occurrence of necrosis during myocardial infarction has been delineated only in permanent occlusion models. An electron microscopy study in 1959 showed that necrosis takes place within one hour of the onset of ischemia.160 In a 1996 study,157 the frequencies of apoptosis and necrosis were evaluated using TUNEL to assess DNA fragmentation and a myosin antibody administered in vivo to assess plasma membrane integrity. Apoptosis was detectable following 2 hours of ischemia (the earliest time point examined), became maximal at 4.5 hours (≈6 000 000 myocytes), and fell off sometime between 6 and 24 hours. In contrast, necrosis was not present at significant levels until 6 hours (≈1 000 000 myocytes) and persisted at these levels until 24 hours. This study concluded that apoptosis is the predominant form of cell death during myocardial infarction, but little was known about the specificities of apoptosis and necrosis markers at that time. Accordingly, it is possible that TUNEL overestimated the frequency of apoptosis at the expense of necrosis as discussed above. In conclusion, the relative frequencies of apoptosis and necrosis in myocardial infarction remain unclear.
Which necrosis pathways are involved in myocardial infarction? Although only primitive knowledge exists at present, the answer appears to be that both the death receptor143 and mitochondrial9,10 pathways mediate cardiac myocyte necrosis during ischemia/reperfusion. A role for the death receptor necrosis pathway is not surprising in light of the involvement of the death receptor apoptosis pathway in myocardial ischemia/reperfusion. For example, infarct size is reduced markedly in mice with Fas loss of function mutations.161,162 Moreover, although the effect of these mutations has been attributed to decreases in apoptosis, it is not clear, from today's perspective, whether changes in necrosis, apoptosis, or both are responsible.
Genetic manipulation of the TNFα signaling axis has provided additional insights into the role of the death receptor necrosis pathway in myocardial infarction. Simultaneous deletion of both TNFR1 and TNFR2 exacerbates infarct size following permanent coronary occlusion.163 Conversely, overexpression of TNFα (at low levels) or TRAF2 on a wild type background ameliorates myocardial damage.164 In the case of TRAF2, this is associated with NF-κB activation. These observations suggest that the survival arm of the death receptor pathway can limit myocardial infarction during ischemia/reperfusion.
The role of the mitochondrial pathway in cardiac myocyte apoptosis is well established. Overexpression of Bcl-2 and loss of function mutations in Bax, Bak, and procaspase-9 reduce infarct size in response to ischemia/reperfusion.20,165–167 The mitochondrial necrosis pathway also plays a central role in myocardial infarction. Deletion of cyclophilin D markedly decreases infarct size during ischemia/reperfusion in vivo9,10 supporting the idea that MPTP opening is involved in pathogenesis. Similarly, cyclosporine A and sanglifehrin A, which bind and inhibit cyclophilin D (discussed above), protect isolated cardiac myocytes from reoxygenation injury,168 and decrease infarction in isolated, perfused hearts and the myocardium in vivo during ischemia/reperfusion.118,169–171
These exciting findings have been translated into a pilot study in humans. Patients with ST-segment elevation acute myocardial infarction received either cyclosporine A (n=30) or saline (n=28) before undergoing percutaneous coronary intervention (angioplasty and stenting).172 Serum creatine kinase (days 1 to 3; P<0.04) and infarct size (day 5, measured by MRI in 27 patients; P<0.04) were decreased in cyclosporine A-treated patients. It is curious, however, that troponin I, a sensitive and specific marker for myocardial infarction, was not significantly affected. Follow-up MRI 6 months later showed cyclosporine A-treated patients exhibited persistent reduction in infarct size (P<0.04) and a nonsignificant trend toward improved left ventricular function. Cardiac mass was similar in treated and control groups, of potential significance in light of the possibility that cyclosporine A might blunt hypertrophy through inhibition of calcineurin.173 Although this study is too small to provide definitive conclusions, the data suggest that cyclosporine A may reduce infarct size in humans. These results need to be confirmed in a larger number of patients.
Heart Failure
In comparison with the massive, short-lived burst of cell death during myocardial infarction, the absolute magnitude of cell death (TUNEL) in failing human hearts is quite low (0.08 to 0.25% of cardiac myocytes), but is of orders of magnitude higher than in control hearts (0.001 to 0.01%).174–176 Moreover, cardiac myocytes continue to die over the course of advanced heart failure, suggesting that low levels of cell death could lead to significant cumulative cardiac myocyte loss. Multiple studies have demonstrated that cardiac myocyte apoptosis is a critical component in the pathogenesis of heart failure. Transgenic experiments demonstrate that very low levels of cardiac myocyte apoptosis (0.023%) are sufficient to cause a lethal cardiomyopathy.158 Conversely, genetic inhibition of cardiac myocyte apoptosis ameliorates heart failure induced by a variety of stimuli.20
The frequency of necrosis in heart failure models has not been studied intensively. Because abnormalities in Ca2+ handling are a component of heart failure and also a trigger of MPTP opening, transgenic mice were created with inducible, cardiac-specific overexpression of the β2a subunit of the L-type Ca2+ channel.13 These mice exhibit Ca2+ overload, spontaneous myocardial necrosis, and heart failure. Interestingly, this phenotype is rescued by the deletion of cyclophilin D (but not Bcl-2 overexpression), implicating necrosis (but not apoptosis) as a causal component in pathogenesis. This conclusion was also tested in a more clinically relevant model of heart failure, doxorubicin-induced cardiomyopathy. The absence of cyclophilin D confers significant protection against heart failure in this model. Taken together, these data raise the possibility of a role for cardiac myocyte necrosis in heart failure.
To test this concept further, mice lacking cyclophilin D have been subjected to hemodynamic overload induced by transverse aortic constriction.114 Unexpectedly, the absence of cyclophilin D was associated with more – not less – heart failure compared with wild type animals. Even more striking, mice lacking cyclophilin D transitioned into heart failure in response to swimming, a classic stimulus for physiological hypertrophy. These phenotypes resulted from the absence of cyclophilin D in cardiac myocytes as the generalized knockouts were rescued by cardiac myocyte-specific transgenic replacement of cyclophilin D. Notably, ppif−/− and wild type mice do not exhibit baseline differences in cardiac function. Rather, differences in heart failure susceptibility are evident only under stress. Because the increased propensity of cyclophilin D–deficient mice for stress-induced heart failure appears to run counter to the benefit that its absence confers on ischemia/reperfusion, other actions of cyclophilin D were sought. NMR spectrometry under basal conditions demonstrated a shift from fatty acid oxidation to glycolysis in cyclophilin D–deficient hearts. In addition, microarray analysis demonstrated increases in pyruvate dehydrogenase and α-ketoglutarate dehydrogenase transcripts. Although corresponding protein levels were unchanged, the activity of each of these enzymes was increased. Pyruvate dehydrogenase and α-ketoglutarate dehydrogenase are mitochondrial matrix proteins that are activated by Ca2+. Mitochondria lacking cyclophilin D or treated with cyclosporine A exhibit increased levels of matrix Ca2+ with decreased Ca2+ efflux. These data suggest a novel physiological function for cyclophilin D in promoting Ca2+ efflux, possibly through MPTP. The relationship between decreased Ca2+ efflux and the stress-induced decompensation exhibited by cyclophilin D–deficient mice as well as the explanation for why cyclophilin D deletion is protective in some heart failure models but not others will require further investigation.
Potential Therapeutic Opportunities
Programmed necrosis of cardiac myocytes is critical in the pathogenesis of myocardial infarction resulting from ischemia/reperfusion and may also play a role in heart failure. Accordingly, there is a strong rationale for seeking pharmacological approaches to inhibit necrosis in heart disease. We consider the merits of various strategies to inhibit necrosis and discuss some currently available drugs.
A key issue for any anti–cell death strategy is whether to target proximal versus distal pathways. An advantage of distal inhibition is that it may avoid the redundancy resulting from multiple proximal inputs. This advantage comes at a price, however, in that distal blockade may not rescue key organelles. For example, caspase inhibitors often fail to preserve mitochondrial function in apoptotic cells. In the case of necrosis, the organelles that need protection are the mitochondria, which sustain considerably more damage than in apoptosis, and the various cell membranes (plasma, ER, and lysosomal). Thus, we suspect that inhibition of proximal pathways will be needed to preserve mitochondrial and membrane function, both of which are critical for cell viability.
Several types of small molecules inhibit proximal events: (1) nec-1,27 which antagonizes the kinase activity of RIP1, blocks the death receptor necrosis pathway; (2) PARP inhibitors177; and (3) cyclosporine A169,170 (and related compounds), which binds cyclophilin D and inhibits its interactions or function, thereby decreasing the likelihood of MPTP opening. Nec-1 appears to reduce infarct size markedly,143 although these data come from a single study with a small number of animals (Table 2). In contrast, substantial data support the notion that cyclosporine A can reduce infarct size in various animal models and perhaps humans. The reported overlap between the effects of nec-1 and cyclophilin D absence on infarct size reduction suggest that there would be little benefit to combining nec-1 with cyclosporine A. However, the effects of combinations of these drugs have been studied in relatively few animals and at only a single time point. There are likely to be some actions of nec-1 that do not overlap with those of cyclosporine A. For these reasons, it will be important to re-evaluate necrosis inhibition by nec-1 and cyclosporine A, alone and in combination.
Concluding Remarks
The recognition that a substantial proportion of necrotic death is regulated impacts on multiple areas of science and medicine. From a fundamental perspective, it raises questions about physiological roles of necrosis, molecular connections between necrosis and other death processes, and evolutionary relationships among various forms of cell death. Necrosis is also tremendously important in the pathogenesis of multiple diseases. From the perspective of heart disease, cardiac myocyte necrosis plays a critical role in myocardial infarction and may also be important in heart failure. The fact that cardiac myocyte necrosis is regulated opens up the possibility of novel pharmacological approaches to inhibiting this form of cell death and limiting cardiac damage and dysfunction.
Acknowledgments
We thank Professors Andrew P. Halestrap and Fabio Di Lisa for helpful discussions.
Footnote
Non-standard Abbreviations and Acronyms
- Δψm
- inner mitochondrial transmembrane potential
- AIF
- apoptosis inducing factor
- Akt
- v-akt (AKR thymoma viral oncogene) homolog serine/threonine kinase
- ANT
- adenine nucleotide translocator
- Bcl
- B-cell lymphoma
- ced
- cell death abnormal
- cIAP
- cellular inhibitor of apoptosis
- CYLD
- cylindromatosis
- DD
- death domain
- ER
- endoplasmic reticulum
- FADD
- Fas-associated via death domain
- GLUD
- glutamate dehydrogenase
- GLUL
- glutamate ammonia ligase
- GSK
- glycogen synthase kinase
- HMG
- high-mobility group protein
- IMM
- inner mitochondrial membrane
- LMP
- lysosomal membrane permeabilization
- MEF
- mouse embryonic fibroblast
- MNNG
- N-methyl-N′-nitro-N′-nitrosoguanidine
- MPTP
- mitochondrial permeability transition pore
- NDUFS
- NADH dehydrogenase Fe-S protein
- Nec
- necrostatin
- Nix/BNip3L
- Nip3-like protein X/Bcl-2-adenovirus E1B 19 kD-interacting protein 3-like protein
- Nox1
- NADPH oxidase
- OMM
- outer mitochondrial membrane
- PARP
- poly(ADP-ribose) polymerase
- PiC
- phosphate carrier
- Pim
- provided insertion site of moloney murine leukemia virus
- PKC
- protein kinase C
- ppif
- peptidylprolyl isomerase F
- PYGL
- glycogen phosphorylase
- RHIM
- RIP homotypic interaction motif
- RIP
- receptor-interacting protein
- ROS
- reactive oxygen species
- SMAC
- second mitochondria-derived activator of caspase
- TNF
- tumor necrosis factor
- TNFR
- tumor necrosis factor receptor
- TRADD
- TNF receptor-associated death domain
- TRAF
- TNFR-associated factor
- TRAIL
- TNF-related apoptosis-inducing ligand
- VDAC
- voltage-dependent anion channel
- z-VADfmk
- benzyloxycarbonyl-valine alanine aspartic acid (O-methyl) fluoromethylketone
Sources of Funding
G.K. was supported by a NIH predoctoral fellowship 5T32AG023475. K.K. was supported by a postgraduate research scholarship from the A. G. Leventis Foundation. R.N.K. was supported by NIH grants 5R01HL060665 and 1R03DA031671, a NYSTEM (New York State Stem Cell Initiative) grant, a Mary Kay Foundation grant, and the generosity of the Wilf Family, Dr Gerald and Myra Dorros Chair in Cardiovascular Disease, and the David Himelberg Foundation.
References
1.
Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol. 1991;7:663–698.
2.
Shaham S, Horvitz HR. Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities. Genes Dev. 1996;10:578–591.
3.
Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205–219.
4.
Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007;14:1237–1243.
5.
Xu K, Tavernarakis N, Driscoll M. Necrotic cell death in C. elegans requires the function of calreticulin and regulators of Ca(2+) release from the endoplasmic reticulum. Neuron. 2001;31:957–971.
6.
Syntichaki P, Xu K, Driscoll M, Tavernarakis N. Specific aspartyl and calpain proteases are required for neurodegeneration in C. elegans. Nature. 2002;419:939–944.
7.
Bianchi L, Gerstbrein B, Frokjaer-Jensen C, Royal DC, Mukherjee G, Royal MA, Xue J, Schafer WR, Driscoll M. The neurotoxic MEC-4(d) DEG/ENac sodium channel conducts calcium: implications for necrosis initiation. Nat Neurosci. 2004;7:1337–1344.
8.
Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–190.
9.
Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658–662.
10.
Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652–658.
11.
Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A. 2005;102:12005–12010.
12.
Kitsis RN, Molkentin JD. Apoptotic cell death “Nixed” by an ER-mitochondrial necrotic pathway. Proc Natl Acad Sci U S A. 2010;107:9031–9032.
13.
Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser SR, Molkentin JD. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007;117:2431–2444.
14.
Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med. 2008;14:1097–1105.
15.
Esposito E, Cuzzocrea S. New therapeutic strategy for Parkinson's and Alzheimer's disease. Curr Med Chem. 2010;17:2764–2774.
16.
Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112–1123.
17.
Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J, Molkentin JD. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med. 2008;14:442–447.
18.
Fujimoto K, Chen Y, Polonsky KS, Dorn GW. Targeting cyclophilin D and the mitochondrial permeability transition enhances beta-cell survival and prevents diabetes in Pdx1 deficiency. Proc Natl Acad Sci U S A.2010;107:10214–10219.
19.
He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100–1111.
20.
Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol. 2010;72:19–44.
21.
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–371.
22.
Fiers W, Beyaert R, Boone E, Cornelis S, Declercq W, Decoster E, Denecker G, Depuydt B, De Valck D, De Wilde G, Goossens V, Grooten J, Haegeman G, Heyninck K, Penning L, Plaisance S, Vancompernolle K, Van Criekinge W, Vandenabeele P, Vanden Berghe W, Van de Craen M, Vandevoorde V, Vercammen D. TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. J Inflamm. 1995;47:67–75.
23.
Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 2005;30:151–159.
24.
Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/Apo-1 (CD95) in yeast and causes cell death. Cell. 1995;81:513–523.
25.
Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007;14:400–410.
26.
Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489–495.
27.
Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick SM, Gerber SA, Lugovskoy A, Yuan J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313–321.
28.
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–119.
29.
Smith CC, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 2007;21:227–233.
30.
Sun X, Yin J, Starovasnik MA, Fairbrother WJ, Dixit VM. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem. 2002;277:9505–9511.
31.
Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215–2223.
32.
Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30:689–700.
33.
Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006;22:245–257.
34.
Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A. 2008;105:11778–11783.
35.
Wong WW, Gentle IE, Nachbur U, Anderton H, Vaux DL, Silke J. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ. 2010;17:482–487.
36.
Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430:694–699.
37.
Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008;135:1311–1323.
38.
Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693–703.
39.
Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR, Salvesen GS. A unified model for apical caspase activation. Mol Cell. 2003;11:529–541.
40.
Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999;13:2514–2526.
41.
Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W, Grooten J, Fiers W, Vandenabeele P. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187:1477–1485.
42.
Ermolaeva MA, Michallet MC, Papadopoulou N, Utermohlen O, Kranidioti K, Kollias G, Tschopp J, Pasparakis M. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol. 2008;9:1037–1046.
43.
Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332–336.
44.
Goossens V, De Vos K, Vercammen D, Steemans M, Vancompernolle K, Fiers W, Vandenabeele P, Grooten J. Redox regulation of TNF signaling. Biofactors. 1999;10:145–156.
45.
Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, Tran JH, Nedospasov SA, Liu ZG. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem. 2004;279:10822–10828.
46.
Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem. 1992;267:5317–5323.
47.
Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell. 2007;26:675–687.
48.
Saelens X, Festjens N, Parthoens E, Vanoverberghe I, Kalai M, van Kuppeveld F, Vandenabeele P. Protein synthesis persists during necrotic cell death. J Cell Biol. 2005;168:545–551.
49.
Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM. Caspase activation inhibits proteasome function during apoptosis. Mol Cell. 2004;14:81–93.
50.
Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002;7:321–328.
51.
Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med. 1997;185:1481–1486.
52.
Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 2008;20:294–302.
53.
Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115–130.
54.
Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, Herceg Z, Wang ZQ, Schulze-Osthoff K. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 2002;13:978–988.
55.
Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, Dawson VL. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med. 1997;3:1089–1095.
56.
Zingarelli B, Hake PW, O'Connor M, Denenberg A, Kong S, Aronow BJ. Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol Med. 2003;9:143–153.
57.
Zhou HZ, Swanson RA, Simonis U, Ma X, Cecchini G, Gray MO. Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts. Am J Physiol Heart Circ Physiol. 2006;291:H714–H723.
58.
Lai Y, Chen Y, Watkins SC, Nathaniel PD, Guo F, Kochanek PM, Jenkins LW, Szabo C, Clark RS. Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury. J Neurochem. 2008;104:1700–1711.
59.
Pankotai E, Lacza Z, Muranyi M, Szabo C. Intra-mitochondrial poly(ADP-ribosyl)ation: potential role for alpha-ketoglutarate dehydrogenase. Mitochondrion. 2009;9:159–164.
60.
Xu Y, Huang S, Liu ZG, Han J. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/Traf2-mediated Jnk1 activation. J Biol Chem. 2006;281:8788–8795.
61.
Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, Dawson VL. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 2002;297:259–263.
62.
Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, Dawson VL. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A. 2006;103:18314–18319.
63.
Moubarak RS, Yuste VJ, Artus C, Bouharrour A, Greer PA, Menissier-de Murcia J, Susin SA. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Mol Cell Biol. 2007;27:4844–4862.
64.
Artus C, Boujrad H, Bouharrour A, Brunelle MN, Hoos S, Yuste VJ, Lenormand P, Rousselle JC, Namane A, England P, Lorenzo HK, Susin SA. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J. 2010;29:1585–1599.
65.
Temkin V, Huang Q, Liu H, Osada H, Pope RM. Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol Cell Biol. 2006;26:2215–2225.
66.
Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99–163.
67.
Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11:700–714.
68.
Berghe TV, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N, Guerin CJ, Brunk UT, Declercq W, Vandenabeele P. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ. 2010;17:922–930.
69.
Goossens V, Stange G, Moens K, Pipeleers D, Grooten J. Regulation of tumor necrosis factor-induced, mitochondria- and reactive oxygen species-dependent cell death by the electron flux through the electron transport chain complex I. Antioxid Redox Signal. 1999;1:285–295.
70.
Wang KK. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23:20–26.
71.
Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, Carafoli E, Nicotera P. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell. 2005;120:275–285.
72.
Kar P, Chakraborti T, Samanta K, Chakraborti S. Mu-calpain mediated cleavage of the Na+/Ca2+ exchanger in isolated mitochondria under A23187 induced Ca2+ stimulation. Arch Biochem Biophys. 2009;482:66–76.
73.
Spencer MJ, Croall DE, Tidball JG. Calpains are activated in necrotic fibers from Mdx dystrophic mice. J Biol Chem. 1995;270:10909–10914.
74.
Harwood SM, Allen DA, Raftery MJ, Yaqoob MM. High glucose initiates calpain-induced necrosis before apoptosis in LLC-PK1 cells. Kidney Int. 2007;71:655–663.
75.
Yamashima T, Tonchev AB, Tsukada T, Saido TC, Imajoh-Ohmi S, Momoi T, Kominami E. Sustained calpain activation associated with lysosomal rupture executes necrosis of the postischemic CA1 neurons in primates. Hippocampus. 2003;13:791–800.
76.
Oikawa S, Yamada T, Minohata T, Kobayashi H, Furukawa A, Tada-Oikawa S, Hiraku Y, Murata M, Kikuchi M, Yamashima T. Proteomic identification of carbonylated proteins in the monkey hippocampus after ischemia-reperfusion. Free Radic Biol Med. 2009;46:1472–1477.
77.
Doulias PT, Kotoglou P, Tenopoulou M, Keramisanou D, Tzavaras T, Brunk U, Galaris D, Angelidis C. Involvement of heat shock protein-70 in the mechanism of hydrogen peroxide-induced DNA damage: the role of lysosomes and iron. Free Radic Biol Med. 2007;42:567–577.
78.
Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Hoyer-Hansen M, Weber E, Multhoff G, Rohde M, Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med. 2004;200:425–435.
79.
Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell Mol Life Sci. 2010;67:1567–1579.
80.
Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27:6434–6451.
81.
Syntichaki P, Samara C, Tavernarakis N. The vacuolar H+ -ATPase mediates intracellular acidification required for neurodegeneration in C. elegans. Curr Biol. 2005;15:1249–1254.
82.
Zhao M, Antunes F, Eaton JW, Brunk UT. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem. 2003;270:3778–3786.
83.
Kurz T, Terman A, Gustafsson B, Brunk UT. Lysosomes in iron metabolism, ageing and apoptosis. Histochem Cell Biol. 2008;129:389–406.
84.
Xie C, Zhang N, Zhou H, Li J, Li Q, Zarubin T, Lin SC, Han J. Distinct roles of basal steady-state and induced H-ferritin in tumor necrosis factor-induced death in L929 cells. Mol Cell Biol. 2005;25:6673–6681.
85.
Yamashima T, Kohda Y, Tsuchiya K, Ueno T, Yamashita J, Yoshioka T, Kominami E. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on ‘calpain-cathepsin hypothesis'. Eur J Neurosci. 1998;10:1723–1733.
86.
Schnitzer E, Pinchuk I, Lichtenberg D. Peroxidation of liposomal lipids. Eur Biophys J. 2007;36:499–515.
87.
Kim C, Kim JY, Kim JH. Cytosolic phospholipase A(2), lipoxygenase metabolites, and reactive oxygen species. BMB Rep. 2008;41:555–559.
88.
Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther. 2009;23:49–59.
89.
Suffys P, Beyaert R, De Valck D, Vanhaesebroeck B, Van Roy F, Fiers W. Tumour-necrosis-factor-mediated cytotoxicity is correlated with phospholipase-A2 activity, but not with arachidonic acid release per se. Eur J Biochem. 1991;195:465–475.
90.
Won JS, Singh I. Sphingolipid signaling and redox regulation. Free Radic Biol Med. 2006;40:1875–1888.
91.
Poppe M, Reimertz C, Munstermann G, Kogel D, Prehn JH. Ceramide-induced apoptosis of D283 medulloblastoma cells requires mitochondrial respiratory chain activity but occurs independently of caspases and is not sensitive to Bcl-xL overexpression. J Neurochem. 2002;82:482–494.
92.
Jayadev S, Hayter HL, Andrieu N, Gamard CJ, Liu B, Balu R, Hayakawa M, Ito F, Hannun YA. Phospholipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells. J Biol Chem. 1997;272:17196–17203.
93.
Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M, Adam D. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med. 2000;192:601–612.
94.
Thon L, Mohlig H, Mathieu S, Lange A, Bulanova E, Winoto-Morbach S, Schutze S, Bulfone-Paus S, Adam D. Ceramide mediates caspase-independent programmed cell death. FASEB J. 2005;19:1945–1956.
95.
Antignani A, Youle RJ. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane? Curr Opin Cell Biol. 2006;18:685–689.
96.
O'Rourke B. Mitochondrial ion channels. Annu Rev Physiol. 2007;69:19–49.
97.
Crompton M, Costi A, Hayat L. Evidence for the presence of a reversible Ca2+-dependent pore activated by oxidative stress in heart mitochondria. Biochem J. 1987;245:915–918.
98.
Crompton M, Ellinger H, Costi A. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J. 1988;255:357–360.
99.
Halestrap AP. Calcium-dependent opening of a non-specific pore in the mitochondrial inner membrane is inhibited at pH values below 7. Implications for the protective effect of low pH against chemical and hypoxic cell damage. Biochem J. 1991; 278(Pt 3): 715– 719.
100.
Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J. 1995; 307(Pt 1): 93– 98.
101.
Hunter FE, Ford L. Inactivation of oxidative and phosphorylative systems in mitochondria by preincubation with phosphate and other ions. J Biol Chem. 1955;216:357–369.
102.
Chappell JB, Crofts AR. Calcium ion accumulation and volume changes of isolated liver mitochondria. Calcium ion-induced swelling. Biochem J. 1965;95:378–386.
103.
Haworth RA, Hunter DR. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys. 1979;195:460–467.
104.
Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem. 1997;272:3346–3354.
105.
Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, Trezeguet V, Lauquin GJ, Brandolin G. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature. 2003;426:39–44.
106.
McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J. 2002;367:541–548.
107.
Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 2004;427:461–465.
108.
Rodic N, Oka M, Hamazaki T, Murawski MR, Jorgensen M, Maatouk DM, Resnick JL, Li E, Terada N. DNA methylation is required for silencing of ANT4, an adenine nucleotide translocase selectively expressed in mouse embryonic stem cells and germ cells. Stem Cells. 2005;23:1314–1323.
109.
McEnery MW, Snowman AM, Trifiletti RR, Snyder SH. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci U S A. 1992;89:3170–3174.
110.
Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol. 2007;9:550–555.
111.
Krauskopf A, Eriksson O, Craigen WJ, Forte MA, Bernardi P. Properties of the permeability transition in VDAC1(-/-) mitochondria. Biochim Biophys Acta. 2006;1757:590–595.
112.
Halestrap AP, Davidson AM. Inhibition of Ca(2+)-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J. 1990;268:153–160.
113.
Connern CP, Halestrap AP. Purification and N-terminal sequencing of peptidyl-prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem J. 1992; 284(Pt 2): 381– 385.
114.
Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, Molkentin JD. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest. 2010;120:3680–3687.
115.
Leung AW, Varanyuwatana P, Halestrap AP. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem. 2008;283:26312–26323.
116.
Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. Biochem J. 1991; 274(Pt 2): 611– 614.
117.
Basso E, Petronilli V, Forte MA, Bernardi P. Phosphate is essential for inhibition of the mitochondrial permeability transition pore by cyclosporin A and by cyclophilin D ablation. J Biol Chem. 2008;283:26307–26311.
118.
Clarke SJ, McStay GP, Halestrap AP. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem. 2002;277:34793–34799.
119.
Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans. 2010;38:841–860.
120.
McNeil PL, Khakee R. Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am J Pathol. 1992;140:1097–1109.
121.
Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell. 1995;80:675–679.
122.
Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423:168–172.
123.
Han R, Bansal D, Miyake K, Muniz VP, Weiss RM, McNeil PL, Campbell KP. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest. 2007;117:1805–1813.
124.
Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, Pan Z, Komazaki S, Brotto M, Takeshima H, Ma J. Mg53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009;11:56–64.
125.
Cai C, Masumiya H, Weisleder N, Pan Z, Nishi M, Komazaki S, Takeshima H, Ma J. MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem. 2009;284:3314–3322.
126.
Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, Nishi M, Takeshima H, Ma J. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem. 2009;284:15894–15902.
127.
Weisleder N, Takeshima H, Ma J. Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle to contribute to cell membrane repair. Commun Integr Biol. 2009;2:225–226.
128.
Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from Mdx mice. Nature. 1988;335:735–738.
129.
Toyo-Oka T, Kawada T, Nakata J, Xie H, Urabe M, Masui F, Ebisawa T, Tezuka A, Iwasawa K, Nakajima T, Uehara Y, Kumagai H, Kostin S, Schaper J, Nakazawa M, Ozawa K. Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci U S A. 2004;101:7381–7385.
130.
Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798–804.
131.
Munoz LE, Peter C, Herrmann M, Wesselborg S, Lauber K. Scent of dying cells: the role of attraction signals in the clearance of apoptotic cells and its immunological consequences. Autoimmun Rev. 2010;9:425–430.
132.
Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545–1556.
133.
Krysko O, De Ridder L, Cornelissen M. Phosphatidylserine exposure during early primary necrosis (oncosis) in JB6 cells as evidenced by immunogold labeling technique. Apoptosis. 2004;9:495–500.
134.
Brouckaert G, Kalai M, Krysko DV, Saelens X, Vercammen D, Ndlovu M, Haegeman G, D'Herde K, Vandenabeele P. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell. 2004;15:1089–1100.
135.
Miyamoto S, Murphy AN, Brown JH. Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue. J Bioenerg Biomembr. 2009;41:169–180.
136.
Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 2008;15:521–529.
137.
Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, Esposito G, Delucchi F, Arcarese M, Alvarez R, Siddiqi S, Emmanuel GN, Wu W, Fischer K, Martindale JJ, Glembotski CC, Leri A, Kajstura J, Magnuson N, Berns A, Beretta RM, Houser SR, Schaefer EM, Anversa P, Sussman MA. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med. 2007;13:1467–1475.
138.
Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, Bolli R, Cardwell EM, Ping P. Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res. 2003;92:873–880.
139.
Ogbi M, Johnson JA. Protein kinase Cepsilon interacts with cytochrome c oxidase subunit IV and enhances cytochrome c oxidase activity in neonatal cardiac myocyte preconditioning. Biochem J. 2006;393:191–199.
140.
Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, Bouchard RJ, Florez-McClure ML, Heidenreich KA. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 2004;24:9993–10002.
141.
Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535–1549.
142.
Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A. 2010;107:726–731.
143.
Lim SY, Davidson SM, Mocanu MM, Yellon DM, Smith CC. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther. 2007;21:467–469.
144.
Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, Huang DC, Strasser A. BMF: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 2001;293:1829–1832.
145.
Vander Heiden MG, Chandel NS, Schumacker PT, Thompson CB. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell. 1999;3:159–167.
146.
Ricci JE, Munoz-Pinedo C, Fitzgerald P, Bailly-Maitre B, Perkins GA, Yadava N, Scheffler IE, Ellisman MH, Green DR. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell. 2004;117:773–786.
147.
Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. Bax and Bak regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science. 2003;300:135–139.
148.
Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, Pozzan T, Korsmeyer SJ. Proapoptotic Bax and Bak regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2005;102:105–110.
149.
Palmer AE, Jin C, Reed JC, Tsien RY. Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci U S A. 2004;101:17404–17409.
150.
Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC, Gietz RD, Greenberg AH. BNIP3 heterodimerizes with Bcl-2/Bcl-x(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem. 2000;275:1439–1448.
151.
Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC, Aronow BJ, Lorenz JN, Dorn GW. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med.2002;8:725–730.
152.
Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, Jones WK, Dorn GW. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of BNip3 restrains postinfarction remodeling in mice. J Clin Invest. 2007;117:2825–2833.
153.
Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation.2008;117:396–404.
154.
Diwan A, Matkovich SJ, Yuan Q, Zhao W, Yatani A, Brown JH, Molkentin JD, Kranias EG, Dorn GW. Endoplasmic reticulum-mitochondria crosstalk in Nix-mediated murine cell death. J Clin Invest.2009;119:203–212.
155.
Chen Y, Lewis W, Diwan A, Cheng EH, Matkovich SJ, Dorn GW. Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci U S A.2010;107:9035–9042.
156.
Klee M, Pallauf K, Alcala S, Fleischer A, Pimentel-Muinos FX. Mitochondrial apoptosis induced by BH3-only molecules in the exclusive presence of endoplasmic reticular Bak. EMBO J. 2009;28:1757–1768.
157.
Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 1996;74:86–107.
158.
Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest. 2003;111:1497–1504.
159.
Christofferson DE, Yuan J. Cyclophilin A release as a biomarker of necrotic cell death. Cell Death Differ. 2010;17:1942–1943.
160.
Caulfield J, Klionsky B. Myocardial ischemia and early infarction: an electron microscopic study. Am J Pathol. 1959;35:489–523.
161.
Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol. 2003;284:H456–H463.
162.
Jeremias I, Kupatt C, Martin-Villalba A, Habazettl H, Schenkel J, Boekstegers P, Debatin KM. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 2000;102:915–920.
163.
Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, Entman ML, Mann DL. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5456–5461.
164.
Burchfield JS, Dong JW, Sakata Y, Gao F, Tzeng HP, Topkara VK, Entman ML, Sivasubramanian N, Mann DL. The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail. 2010;3:157–164.
165.
Brocheriou V, Hagege AA, Oubenaissa A, Lambert M, Mallet VO, Duriez M, Wassef M, Kahn A, Menasche P, Gilgenkrantz H. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med. 2000;2:326–333.
166.
Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol. 2001;280:H2313–H2320.
167.
Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol. 2003;284:H2351–H2359.
168.
Nazareth W, Yafei N, Crompton M. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A. J Mol Cell Cardiol. 1991;23:1351–1354.
169.
Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol. 1993;25:1461–1469.
170.
Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res. 2003;60:617–625.
171.
Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38:367–374.
172.
Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–481.
173.
Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I, Cung TT, Sportouch C, Angoulvant D, Finet G, Andre-Fouet X, Derumeaux G, Piot C, Vernhet H, Revel D, Ovize M. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:1200–1205.
174.
Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA, Kajstura J, Anversa P. Myocyte death in the failing human heart is gender dependent. Circ Res. 1999;85:856–866.
175.
Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131–1141.
176.
Saraste A, Pulkki K, Kallajoki M, Heikkila P, Laine P, Mattila S, Nieminen MS, Parvinen M, Voipio-Pulkki LM. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest. 1999;29:380–386.
177.
Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007;25:235–260.
178.
Khalil PN, Neuhof C, Huss R, Pollhammer M, Khalil MN, Neuhof H, Fritz H, Siebeck M. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol. 2005;528:124–131.
179.
Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest. 2010;120:1140–1150.
Information & Authors
Information
Published In
Copyright
© 2011 American Heart Association, Inc.
History
Received: 20 January 2011
Revision received: 19 February 2011
Accepted: 9 March 2011
Published online: 15 April 2011
Published in print: 15 April 2011
Keywords
Subjects
Authors
Disclosures
None.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- MLKL triggers NLRP3 activation in sodium arsenite-induced myocardial necroinflammation, Toxicology, 515, (154132), (2025).https://doi.org/10.1016/j.tox.2025.154132
- The impact of aging and biological sex on cardiac collagen metabolism, Mechanisms of Ageing and Development, 226, (112079), (2025).https://doi.org/10.1016/j.mad.2025.112079
- Necroptosis: a significant and promising target for intervention of cardiovascular disease, Biochemical Pharmacology, 237, (116951), (2025).https://doi.org/10.1016/j.bcp.2025.116951
- Gemfibrozil mitigates caspase-11-driven myocardial pyroptosis in ischemia/reperfusion injury in mice, Journal of Molecular and Cellular Cardiology Plus, 12, (100292), (2025).https://doi.org/10.1016/j.jmccpl.2025.100292
- Egg Overactivation—An Overlooked Phenomenon of Gamete Physiology, International Journal of Molecular Sciences, 26, 9, (4163), (2025).https://doi.org/10.3390/ijms26094163
- Long non-coding RNA AK023617 orchestrates atherosclerosis by regulating the circadian rhythm of immunity-related GTPase family M protein in macrophages, Non-coding RNA Research, 11, (262-272), (2025).https://doi.org/10.1016/j.ncrna.2024.12.008
- Cardiac preservation using ex vivo organ perfusion: new therapies for the treatment of heart failure by harnessing the power of growth factors using BMP mimetics like THR-184, Frontiers in Cardiovascular Medicine, 12, (2025).https://doi.org/10.3389/fcvm.2025.1535778
- Mitochondria associated membranes in dilated cardiomyopathy: connecting pathogenesis and cellular dysfunction, Frontiers in Cardiovascular Medicine, 12, (2025).https://doi.org/10.3389/fcvm.2025.1571998
- Simvastatin and rosuvastatin attenuate necroptosis in rat failing hearts following myocardial infarction; the contribution of Hsp90 inhibition in cardiomyocytes to prevent necroptosis, Biochemical Pharmacology, 233, (116792), (2025).https://doi.org/10.1016/j.bcp.2025.116792
- Curcumin exerts protective effects against doxorubicin-induced cardiotoxicity, The Ukrainian Biochemical Journal, 97, 1, (25-43), (2025).https://doi.org/10.15407/ubj97.01.025
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.